SPRY — ARS Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-12-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on SPRY
| date | signal | measured base rate |
|---|---|---|
| 2026-08-21 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-18 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-29 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-20 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-25 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-29 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-12 | Karas Eric Chief Commercial Officer | Open-market sale 10b5-1 plan | 25.0K | 10.00 | 250.0K |
| 2026-06-12 | Karas Eric Chief Commercial Officer | Option exercise 10b5-1 plan | 25.0K | 1.50 | 37.5K |
| 2026-06-12 | Fitzpatrick Alexander A Chief Legal Officer | Open-market sale 10b5-1 plan | 3.4K | 10.00 | 33.5K |
| 2025-11-13 | Dorsey Brian Chief Operating Officer | Open-market sale | 21.8K | 8.71 | 190.1K |
| 2025-11-13 | Dorsey Brian Chief Operating Officer | Option exercise | 21.8K | 0.64 | 14.0K |
| 2025-11-12 | Chakma Justin Chief Business Officer | Open-market sale | 136.4K | 8.86 | 1.2M |
| 2025-11-12 | Chakma Justin Chief Business Officer | Open-market sale | 30.0K | 8.91 | 267.3K |
| 2025-11-12 | Chakma Justin Chief Business Officer | Option exercise | 30.0K | 0.84 | 25.2K |
| 2025-11-12 | Shah Pratik Director | Gift | 250.0K | 0.00 | 0 |
| 2025-11-12 | Shah Pratik Director | Gift | 100.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 87.2M | 10.9M |
| ORBIMED ADVISORS LLC | 66.6M | 8.3M |
| Rubric Capital Management LP | 64.2M | 8.0M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 60.3M | 7.5M |
| MILLENNIUM MANAGEMENT LLC | 48.0M | 6.0M |
| BlackRock, Inc. | 40.2M | 5.0M |
| Aberdeen Group plc | 33.0M | 4.1M |
| SR One Capital Management, LP | 32.2M | 4.0M |
| STATE STREET CORP | 29.3M | 3.6M |
| FRANKLIN RESOURCES INC | 26.3M | 3.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 144 | 2026-08-20 | — | on EDGAR ↗ |
| 144 | 2026-08-20 | — | on EDGAR ↗ |
| 144 | 2026-08-19 | — | on EDGAR ↗ |
| 144 | 2026-08-19 | — | on EDGAR ↗ |
| 144 | 2026-08-18 | — | on EDGAR ↗ |
| 144 | 2026-08-18 | — | on EDGAR ↗ |
| 3 | 2026-08-17 | 2026-08-17 | on EDGAR ↗ |
| 10-Q | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY · 2026-08-20
- ARS Pharmaceuticals, Inc. (SPRY) filed form 144 · 2026-08-20 · SEC EDGAR
- ARS Pharmaceuticals, Inc. (SPRY) filed form 144 · 2026-08-20 · SEC EDGAR
- ARS Pharmaceuticals, Inc. (SPRY) filed form 144 · 2026-08-19 · SEC EDGAR
- ARS Pharmaceuticals, Inc. (SPRY) filed form 144 · 2026-08-19 · SEC EDGAR
- ARS Pharmaceuticals, Inc. (SPRY) filed form 144 · 2026-08-18 · SEC EDGAR
Ask the AI about SPRY
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →